Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton's Jelly, an Extraembryonic Source.
Fiche publication
Date publication
décembre 2019
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle, Pr DECOT Véronique, Dr REPPEL Loïc
Tous les auteurs :
Laroye C, Gauthier M, Antonot H, Decot V, Reppel L, Bensoussan D
Lien Pubmed
Résumé
Many clinical trials report mesenchymal stem/stromal cells (MSCs) efficacy in various indications. Therefore, standardization of MSC production becomes necessary. MSC properties are impacted by tissue origin, especially if they are from extraembryonic tissue or adult sources. For this reason, we evaluated the impact of MSC tissue origin on production.
Mots clés
Wharton’s jelly, bone marrow, good manufacturing practice, mesenchymal stem/stromal cells
Référence
J Clin Med. 2019 Dec 14;8(12):